Answers are grounded in this paper and cite their sources.
Chimeric antigen receptor targets leukemia cells in models and humanized mice, suggesting antileukemia potential.
Description Targeting acute myeloid leukemia (AML) with chimeric antigen receptor (CAR)-T cells that recognize conventional myeloid-associated antigens expressed on the cell surface of blastic cells causes depletion of normal myeloid progenitor cells. Cathepsin-G (CG1) is a myeloid-restricted protein normally stored in azurophil granules but broadly expressed in the cytoplasm of leukemic blasts. In leukemic blasts, CG1 is processed, and the CG1-derived peptides are presented by the major histocompatibility complex and recognized by CD8 T cells. We developed a CAR that selectively targets an HLA-A2–restricted CG1 peptide in the CG1 peptide/HLA-A2 complex. Next, we enhanced the CAR to reach a functional avidity approximating that of a conventional alpha-beta T-cell receptor recognizing a peptide/HLA complex. Specifically, CAR-T cells with duplicated CD3ζ ITAM and overexpression of kinase LcK showed recognition of target cells presenting less than 0.025 uM of CG1 peptide. The enhanced CAR-T cells exhibited faster CD3ζ phosphorylation without significant modification of their molecular signature and a more robust metabolic profile than did conventional CAR-T cells. Furthermore, the enhanced CAR-T cells displayed significant antileukemia effects in vitro, in three independent AML PDX models, and in humanized mice without showing hematopoietic toxicity. Our findings demonstrate the clinical potential of CG1-specific CAR-T cells for the treatment of AML.
No takes yet. Share an insight, caveat, or question.
Walhart et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: